Contrasting PROCEPT BioRobotics (NASDAQ:PRCT) & Revolutions Medical (OTCMKTS:RMCP)

Revolutions Medical (OTCMKTS:RMCP) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Risk & Volatility

Revolutions Medical has a beta of -0.43, indicating that its stock price is 143% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.

Insider and Institutional Ownership

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 10.5% of Revolutions Medical shares are held by company insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Revolutions Medical and PROCEPT BioRobotics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolutions Medical	0	0	0	0	N/A
PROCEPT BioRobotics	0	0	7	0	3.00

PROCEPT BioRobotics has a consensus target price of $78.17, suggesting a potential downside of 1.71%. Given PROCEPT BioRobotics’ higher possible upside, analysts plainly believe PROCEPT BioRobotics is more favorable than Revolutions Medical.

Profitability

This table compares Revolutions Medical and PROCEPT BioRobotics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revolutions Medical	N/A	N/A	N/A
PROCEPT BioRobotics	-58.73%	-37.85%	-26.20%

Earnings & Valuation

This table compares Revolutions Medical and PROCEPT BioRobotics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolutions Medical	N/A	N/A	N/A	N/A	N/A
PROCEPT BioRobotics	$176.58 million	23.16	-$105.90 million	($2.12)	-37.51

Revolutions Medical has higher earnings, but lower revenue than PROCEPT BioRobotics.

Summary

PROCEPT BioRobotics beats Revolutions Medical on 6 of the 9 factors compared between the two stocks.

About Revolutions Medical

Revolutions Medical Corporation, a development stage company, is engaged in the design, development, and commercialization of auto retractable vacuum safety syringes in the United States and internationally. The company develops RevVac auto retractable vacuum safety syringe, which is designed to reduce accidental needle stick injuries and lower the spread of blood borne diseases. It is also developing a suite of magnetic resonance imaging software tools consisting of RevColor, Rev3D, RevDisplay, and RevScan that are designed to enhance general diagnostic confidence through education and research use. The company sells its products to acute care hospitals, alternate care facilities, doctors' offices, clinics, emergency centers, surgical centers, convalescent hospitals, veterans administration facilities, military organizations, public health facilities, and prisons through distributors. Revolutions Medical Corporation was founded in 1996 and is headquartered in Charleston, South Carolina.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.